Indian Pharma Companies Urge Government To Fend Off US Demand

The Indian Pharmaceutical Alliance (IPA) shot off a letter that had pointed to issues related to intellectual property laws in India to the industry minister.

Indian drugmakers urged the government not to give in to mounting pressure from a section of US senators for tighter intellectual property (IP) laws in India. They said that this will hurt the domestic industry and impede consumers' access to affordable healthcare.

There is a race among the multinational companies for inclusion of two key provisions in the Indian Patents Act data exclusivity and patent linkages.

Indian Pharma Industry Has Enormous Opportunities To Discover New Drugs: Sun Pharma
Pharmaceutical companies are setting up labs abroad due to lack of expertise in India, so the core areas such as clinical development and research capabilities should be strengthened.

Orrin Hatch and Ron Wyden of the Senate Committee on Finance and Paul Ryan and Sandy Levin, House Committee on Ways and Means, in a letter to US secretary of state John Kerry and Penny Pritzker, US secretary of commerce expressed concerns about India's "insufficient respect for and enforcement of patents, most notably relating to biopharmaceuticals. We must make meaningful progress in addressing the significant barriers that India has erected."

While the letter had broad references to areas of business interest such as agriculture and copyrights, it pointed to issues related to intellectual property laws in India.

Indian Pharma Companies Need Strong Digital Dose: D Yellow Elephant Study
Indian pharma sector -- whether Indian companies or global players, lag behind their international counterparts by at least 5-7 years on digital platforms.

IPA secretary general DG Shah said that the demand for patent linkage on India exceeds the current regulations in the US itself. "The USA is pressurizing India to provide what is not in their own law," Shah wrote in his letter to Sitharaman.

The US regulator grants marketing approvals to the second and the subsequent applicants irrespective of the patent status and it is then left to the applicant to wait for the expiry of patent or to launch the product at risk.

Indian Pharmaceutical�s US Branch Faces Lawsuit From Ex-Employees
Sun Pharma faces charges of violating the Worker Adjustment and Retraining Notification Act, where companies must give 60 days' notice before a plant is shut down.

Source: Medindia

Indian Pharmaceutical Company Recalls Anti-seizure and Hypertension Drugs from US Market
Hyderabad-based Dr Reddy’s Laboratories recalled the drugs as the tablets failed dissolution test and some are close to expiry date.